These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21548834)

  • 1. Tasimelteon for insomnia.
    Lankford DA
    Expert Opin Investig Drugs; 2011 Jul; 20(7):987-93. PubMed ID: 21548834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders.
    Hardeland R
    Curr Opin Investig Drugs; 2009 Jul; 10(7):691-701. PubMed ID: 19579175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.
    Bonacci JM; Venci JV; Gandhi MA
    J Pharm Pract; 2015 Oct; 28(5):473-8. PubMed ID: 25092604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tasimelteon for the treatment of non-24-hour sleep-wake disorder.
    Neubauer DN
    Drugs Today (Barc); 2015 Jan; 51(1):29-35. PubMed ID: 25685859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.
    Johnsa JD; Neville MW
    Ann Pharmacother; 2014 Dec; 48(12):1636-41. PubMed ID: 25204464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tasimelteon: a selective and unique receptor binding profile.
    Lavedan C; Forsberg M; Gentile AJ
    Neuropharmacology; 2015 Apr; 91():142-7. PubMed ID: 25534555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tasimelteon for treating non-24-h sleep-wake rhythm disorder.
    Nishimon S; Nishimon M; Nishino S
    Expert Opin Pharmacother; 2019 Jun; 20(9):1065-1073. PubMed ID: 30990759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.
    Leger D; Quera-Salva MA; Vecchierini MF; Ogrizek P; Perry CA; Dressman MA
    Expert Opin Drug Saf; 2015; 14(11):1673-85. PubMed ID: 26393492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder.
    Med Lett Drugs Ther; 2014 Apr; 56(1441):34-5. PubMed ID: 24759294
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.
    Stahl SM
    CNS Spectr; 2014 Dec; 19(6):475-8. PubMed ID: 25422900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders.
    Laudon M; Frydman-Marom A
    Int J Mol Sci; 2014 Sep; 15(9):15924-50. PubMed ID: 25207602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melatonin and Melatonin Agonists as Adjunctive Treatments in Bipolar Disorders.
    Geoffroy PA; Etain B; Franchi JA; Bellivier F; Ritter P
    Curr Pharm Des; 2015; 21(23):3352-8. PubMed ID: 26088111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs for insomnia.
    Zisapel N
    Expert Opin Emerg Drugs; 2012 Sep; 17(3):299-317. PubMed ID: 22681198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment.
    Torres R; Kramer WG; Baroldi P
    J Clin Pharmacol; 2015 May; 55(5):525-33. PubMed ID: 25450415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic evaluation of ramelteon : an insomnia therapy.
    Spadoni G; Bedini A; Lucarini S; Mor M; Rivara S
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1145-56. PubMed ID: 25956235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients.
    Edmonds C; Swanoski M
    Consult Pharm; 2017 Mar; 32(3):156-160. PubMed ID: 28270270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New and emerging pharmacotherapeutic approaches for insomnia.
    Neubauer DN
    Int Rev Psychiatry; 2014 Apr; 26(2):214-24. PubMed ID: 24892896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tasimelteon approved for circadian disorder in blind adults.
    Traynor K
    Am J Health Syst Pharm; 2014 Mar; 71(5):350. PubMed ID: 24534583
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon.
    Pandi-Perumal SR; Srinivasan V; Poeggeler B; Hardeland R; Cardinali DP
    Nat Clin Pract Neurol; 2007 Apr; 3(4):221-8. PubMed ID: 17410109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy of insomnia.
    Ioachimescu OC; El-Solh AA
    Expert Opin Pharmacother; 2012 Jun; 13(9):1243-60. PubMed ID: 22578014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.